Hervycta 440Mg Inj

Hervycta 440Mg Inj is an anti-cancer medicine used in the treatment of HER2-positive Breast cancer and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. Cancer is a disease where the cells grow abnormally and divide uncontrollably. It can also be used when the cancer has spread to other parts of the body.

Hervycta 440Mg Inj contains Trastuzumab as an active ingredient, which belongs to the class of monoclonal antibodies. It works by inhibiting the abnormal growth of cancer cells and, finally, causes the initiation of programmed cell death.

Hervycta 440Mg Inj may cause certain side effects such as abdominal pain, chills, diarrhoea, fatigue, nausea, back pain, bone pain, edema, insomnia, fever, dizziness, headache, vomiting, cough, rash, and injection site reactions. If the side effects persist or bother you, please consult your doctor. Hervycta 440Mg Inj will be administered by a trained doctor. Hence, do not self-administer.

Avoid taking it and inform your doctor if you are allergic to Hervycta 440Mg Inj or its components. Inform your doctor if you have any cardiovascular conditions, lung problems, or liver/kidney disease, as it can cause adverse effects. Hervycta 440Mg Inj is known to cause embryo-fetal toxicity. Hence, if you are pregnant or breastfeeding, inform your doctor beforehand.

Hervycta 440Mg Inj contains Trastuzumab, which is used for treating patients with HER2-positive breast cancer and HER2-positive metastatic gastroesophageal adenocarcinoma. This medicine works by inhibiting the excess production of a human epidermal growth factor receptor 2 (HER2) protein in the mammalian cells. This causes inhibition of the cancer cell growth and, finally, initiation of programmed cell death.

Hervycta 440Mg Inj should be avoided if you are allergic to it or any other components of this medicine. Inform your doctor if you have any lung problems, cardiovascular conditions or liver/kidney disease, as it can cause adverse effects. Hervycta 440Mg Inj may cause left ventricular ejection fraction, cardiomyopathy, pulmonary toxicity, exacerbations of chemotherapy-induced neutropenia, and hypersensitivity reactions during the treatment. Hence, careful observation should be performed for any reactions in the patient. Hervycta 440Mg Inj may cause embryo-fetal toxicity. Hence, if you are pregnant or planning to become pregnant, inform your doctor beforehand. Breastfeeding should be discontinued in nursing mothers during the treatment. Hervycta 440Mg Inj is not recommended for use in children as the safety and efficacy are not established.

• Avoid intercourse while on treatment with Hervycta 440Mg Inj.
• Regular, complete blood count monitoring is advised during the treatment.
• All patients should be tested for HER2 test before starting the treatment regimen.
• Liver function tests (LFT) and pulmonary function tests (PFT) should be performed before starting the treatment and every 4 to 6 weeks during the treatment.
• Regular ECG and electrolytes should be monitored while taking the medicine.